Barcelona, Spain – October 15, 2025 – Gilead Sciences, Inc. (NASDAQ: GILD) unveiled new data across its HIV prevention and treatment portfolio at the 20th European AIDS Conference (EACS) 2025, reaffirming its leadership in antiretroviral innovation and long-acting therapeutic development. The findings highlight progress in lenacapavir-based regimens and combination strategies, underscoring the company’s ongoing commitment to advancing next-generation HIV therapies that address resistance, adherence, and global prevention challenges.
Science Significance
The data presented at EACS 2025 emphasize the scientific evolution of HIV care through mechanistically distinct and long-acting agents. Among the most significant findings were new analyses on lenacapavir (Sunlenca®), Gilead’s first-in-class capsid inhibitor, demonstrating durable virologic suppression and strong tolerability profiles when administered every six months. Additional Phase 2 and 3 studies explored combination strategies of lenacapavir with investigational agents targeting multiple HIV lifecycle stages, providing the foundation for potential ultra-long-acting regimens. These results represent a pivotal moment in the transition from daily oral therapy to sustained-release prevention and treatment, supporting Gilead’s goal of achieving functional cures and durable remission in people living with HIV.
Regulatory Significance
The new data contribute to Gilead’s expanding regulatory dossier and align with ongoing submissions to global health authorities for label expansion of lenacapavir in both treatment-experienced and prevention populations. The results reinforce EMA and FDA regulatory pathways for innovative delivery modalities such as biannual subcutaneous injections and combination regimens designed to enhance adherence and reduce resistance. The findings also reflect Gilead’s collaboration with international regulatory agencies to establish harmonized standards for long-acting antiviral therapies, a growing focus within ICH Q12 post-approval lifecycle frameworks and global access programs.
Business Significance
Advertisement
Commercially, the EACS 2025 data solidify Gilead’s strategic leadership in HIV therapeutics, positioning the company to extend its market share in a sector projected to exceed $35 billion globally by 2030. The company’s continued investment in long-acting and combination antiviral R&D reinforces its competitive advantage against peers in the evolving HIV prevention and treatment ecosystem. Moreover, Gilead’s focus on scientific differentiation—through novel mechanisms such as capsid inhibition and maturation blockade—ensures long-term sustainability of its infectious disease portfolio, while supporting collaborative innovation partnerships with research institutions and NGOs to accelerate access globally.
Patients’ Significance
For patients and people at risk of HIV, these findings represent meaningful progress toward more flexible, tolerable, and stigma-reducing care options. Long-acting injectable regimens like lenacapavir promise to reduce pill fatigue, simplify adherence, and improve treatment satisfaction—critical factors in achieving undetectable viral loads and transmission prevention. The data also highlight the potential of integrating preventive agents into community health frameworks, expanding reach to underserved populations, including women and adolescents disproportionately impacted by HIV. Gilead’s patient-centered innovation strategy aims to ensure that scientific breakthroughs translate into accessible, real-world health benefits.
Policy Significance
The announcement carries major implications for public health policy and HIV eradication goals. The emergence of long-acting therapies and durable prevention tools supports global targets set by UNAIDS and the World Health Organization (WHO) to end the HIV epidemic by 2030. These data provide policymakers with robust evidence to support funding, access, and adoption of novel regimens within national HIV programs. Moreover, Gilead’s continued collaborations with governments and global health organizations demonstrate the importance of public–private partnerships in advancing equitable access and improving long-term outcomes for people living with HIV.
The presentation of Gilead’s new HIV data at EACS 2025 marks a defining moment in the pursuit of next-generation HIV prevention and treatment solutions. By combining scientific rigor, regulatory momentum, and patient-centered innovation, Gilead continues to lead the evolution of antiviral medicine. As lenacapavir and its combination regimens advance toward broader global approval, the company’s data-driven approach reaffirms its mission to end the HIV epidemic through sustained innovation, accessibility, and community engagement.
Source: Gilead Sciences, Inc. press release
